Drug intelligence / Profile preview

HT001

Development stage: Phase 2
Lead developer: Hoth Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Injection

Overview

HT001 is a frameshift peptide (FSP) developed by Oryx GmbH & Co. KG. It is a component of a therapeutic vaccine designed to treat advanced microsatellite unstable (MSI-H) colorectal cancer. The vaccine, which also includes AIM2(-1) and TAF1B(-1) peptides along with the adjuvant Montanide® ISA-51 VG, aims to induce or enhance immune responses against MSI-induced FSPs that are shared by the majority of MSI-H colorectal cancers. The goal is to demonstrate the safety and efficacy of vaccination against MSI-induced FSPs in generating immune responses against MSI-H colorectal cancer-associated antigens.

Other names: HT001(-1)

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on HT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT001.

Explore the full profile